創建集團控股(01609.HK)擬折讓約12.78%增發4549萬股 淨籌2.634億港元
格隆匯 4 月 26日丨創建集團控股(01609.HK)公吿,於2021年4月26日,公司與不少於六名認購方訂立認購協議,據此,在認購協議所載條款及條件的規限下,認購方已有條件同意認購,而公司已有條件同意配發及發行合共4549萬股新股份,認購價為每股股份5.8港元。 認購價較於2021年4月23日收市價每股股份6.65港元折讓約12.78%。
認購股份數目相當於緊隨完成後經擴大的已發行股份總數約4.02%。發行認購股份的所得款項淨額2.634億港元。公司擬將所得款項淨額用於潛在收購或投資機會及集團的一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.